- Home
- RNP vs NTLA Comparison
RNP vs NTLA Comparison
Compare RNP & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- NTLA
- Stock Information
- Founded
- RNP 2003
- NTLA 2014
- Country
- RNP United States
- NTLA United States
- Employees
- RNP N/A
- NTLA N/A
- Industry
- RNP Investment Managers
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RNP Finance
- NTLA Health Care
- Exchange
- RNP Nasdaq
- NTLA Nasdaq
- Market Cap
- RNP 1.1B
- NTLA 1.2B
- IPO Year
- RNP N/A
- NTLA 2016
- Fundamental
- Price
- RNP $22.66
- NTLA $13.60
- Analyst Decision
- RNP
- NTLA Buy
- Analyst Count
- RNP 0
- NTLA 19
- Target Price
- RNP N/A
- NTLA $35.11
- AVG Volume (30 Days)
- RNP 117.6K
- NTLA 4.7M
- Earning Date
- RNP 01-01-0001
- NTLA 08-07-2025
- Dividend Yield
- RNP 7.94%
- NTLA N/A
- EPS Growth
- RNP N/A
- NTLA N/A
- EPS
- RNP N/A
- NTLA N/A
- Revenue
- RNP N/A
- NTLA $45,569,000.00
- Revenue This Year
- RNP N/A
- NTLA N/A
- Revenue Next Year
- RNP N/A
- NTLA N/A
- P/E Ratio
- RNP N/A
- NTLA N/A
- Revenue Growth
- RNP N/A
- NTLA N/A
- 52 Week Low
- RNP $15.52
- NTLA $5.90
- 52 Week High
- RNP $21.27
- NTLA $27.42
- Technical
- Relative Strength Index (RSI)
- RNP 55.70
- NTLA 65.69
- Support Level
- RNP $22.31
- NTLA $12.48
- Resistance Level
- RNP $22.99
- NTLA $14.61
- Average True Range (ATR)
- RNP 0.24
- NTLA 0.90
- MACD
- RNP -0.04
- NTLA 0.13
- Stochastic Oscillator
- RNP 50.74
- NTLA 76.33
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.